Study for Adults with High-Risk Liver Disease
Protocol: STUDY00009972
Full Title
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01; N1T-MC-RT01
Description
The University at Buffalo is running a new multi-site study for adults that have high-risk liver disease. Adults living with high-risk liver disease have a greater chance of experiencing serious complications from the disease. The research team is looking to see if a new medication can help to treat high-risk liver disease.

The study will last for about 5 years. After a 12-week screening period, participants will be randomly assigned (which happens by chance, like flipping a coin) to one of the following groups:
-Group 1: will receive a placebo (which looks like the study medicine but does not contain any active medication)
-Both Groups 2 & 3 will receive study medicine randomly chosen that is used for the treatment of the liver disease; however, Group 3 will receive a different study medicine from Group 2’s liver medicine.

During the study, all patients will receive physical exams, blood tests, imaging tests, and other surveys will be completed.
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
-Adults 18 years or older
-Have been diagnosed with high-risk liver disease
-Not currently pregnant
Age Group: Adults
Principal Investigator: AJAY CHAUDHURI
ClinicalTrials.gov: Open Study
Contact(s)
RICHARD REJMAN
rmrejman@buffalo.edu
+1 716-878-3320
LYNN JAGODZINSKI
lynnjago@buffalo.edu
+1 716-888-4843

Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions